Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to 11.94%.

  • Protalix BioTherapeutics' EBIT Margin fell 102900.0% to 11.94% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.3%, marking a year-over-year increase of 298000.0%. This contributed to the annual value of 7.34% for FY2024, which is 86400.0% down from last year.
  • As of Q3 2025, Protalix BioTherapeutics' EBIT Margin stood at 11.94%, which was down 102900.0% from 7.48% recorded in Q2 2025.
  • Over the past 5 years, Protalix BioTherapeutics' EBIT Margin peaked at 58.22% during Q2 2023, and registered a low of 142.62% during Q2 2021.
  • In the last 5 years, Protalix BioTherapeutics' EBIT Margin had a median value of 22.03% in 2022 and averaged 27.9%.
  • Its EBIT Margin has fluctuated over the past 5 years, first plummeted by -1221900bps in 2021, then surged by 1213300bps in 2023.
  • Over the past 5 years, Protalix BioTherapeutics' EBIT Margin (Quarter) stood at 66.74% in 2021, then soared by 57bps to 28.95% in 2022, then crashed by -85bps to 53.55% in 2023, then skyrocketed by 174bps to 39.57% in 2024, then crashed by -70bps to 11.94% in 2025.
  • Its EBIT Margin stands at 11.94% for Q3 2025, versus 7.48% for Q2 2025 and 40.99% for Q1 2025.